News

Video: Global Fund Impact in Indonesia

The Global Fund to fight AIDS, Tuberculosis and Malaria has had a positive impact in Indonesia helping the country leverage local and national funding for its programmes. The video presents interviews with a diverse range of stakeholders and touches on issues around financial accountability, the need for programme implementers to have more training to manage TB, HIV or malaria programs, raises fears of people living with HIV about starting on anti-retroviral therapy and adhering to treatment and presents views on the scaling up treatment to meet MDGs targets.

Another perspective from Kenya:

Spotlight: Mixed perceptions of the Global Fund in Kenya by Henry Neondo, Kenya

Funding for health should begin targeting prevention programmes that address issues that affect women and children, and the Global Fund to fight HIV/AIDS, TB and Malaria (The Global Fund) has a key role to play.

In the context of HIV, Professor Alloys Orago, Director of the National AIDS Control Council (NACC), says “for every one person put on treatment, two more get newly infected – women and the youth still bearing the brunt of the three most burdened some diseases: HIV, tuberculosis and malaria.”

For full text to article by , click here.

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...